I note in the pre-clinical lab tests on mice that there were significant results:
"We obtained 100% protection with a codon-optimized, non-ubiquitinated gD2 construct"
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0076407
Given US population is 300,000,000
Prevalence of HSV2 ~ 1 in 6
Which equates to 50,000,000 people infected
Assume a dose is a reasonable $100
Given theres no viable alternative assume 40% market penetration
Gives Revenue
50,000,000 x 0.40 x 100 = 2,000,000,000
2 Billion
Assume NPAT is 16%
2,000,000,000 x 0.16 = 320,000,000
320 Million
Assume another 50 million in shares is raised taking total to 250,000,000
Gives EPS
320,000,000 / 250,000,000 = 1.28
Assume P/E of 15
Gives a price
1.28 x 15 = 19.02
19.02 price target without including Cardiocel and Infusion products
- Forums
- ASX - By Stock
- HSV-2 Vax Results
I note in the pre-clinical lab tests on mice that there were...
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
(20min delay)
|
|||||
Last
$12.20 |
Change
-0.290(2.32%) |
Mkt cap ! $257.9M |
Open | High | Low | Value | Volume |
$12.49 | $12.50 | $11.80 | $396.0K | 32.70K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 923 | $11.80 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$12.20 | 1821 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 923 | 11.800 |
1 | 80 | 11.750 |
2 | 772 | 11.600 |
2 | 2000 | 11.500 |
1 | 1500 | 11.350 |
Price($) | Vol. | No. |
---|---|---|
12.200 | 1821 | 1 |
12.300 | 3000 | 1 |
12.850 | 99 | 1 |
13.000 | 2000 | 1 |
13.300 | 200 | 1 |
Last trade - 16.10pm 30/09/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |